[
    {
        "trialName": "A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors",
        "nctNumber": "NCT05007106",
        "status": "RECRUITING",
        "studyType": "INTERVENTIONAL",
        "studyPhases": [
            "PHASE2"
        ],
        "primaryCompletionDate": {
            "date": "2027-02-22",
            "type": "ESTIMATED"
        },
        "completionDate": {
            "date": "2027-02-22",
            "type": "ESTIMATED"
        },
        "startDate": "2021-09-16",
        "startDateType": "ACTUAL",
        "durationDays": 1985,
        "daysUntilEnd": 935
    }
]